QLT announces Visudyne(R) sales for fourth quarter and fiscal year 2007

    VANCOUVER, Jan. 17 /CNW/ - QLT Inc. (NASDAQ:  QLTI; TSX:QLT) today reported
that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin)
product of US$45.5 million for the quarter and US$214.9 million for the full
year ended December 31, 2007. Visudyne sales for the fourth quarter declined
by 40.5% over the same quarter in 2006 and the full year represented a
decrease of 39.3% over annual sales in 2006. Visudyne sales in the U.S. for
the quarter were approximately US$10 million, representing 22% of total sales
for the quarter. U.S. average daily Visudyne sales increased to 127 vials in
the fourth quarter of 2007 compared to 118 vials in the third quarter of 2007.
The growth in daily Visudyne vial sales translates to a US$0.6 million
increase quarter over quarter.
    QLT will release its full financial results on Thursday, February 21,
2008, at 7:30 a.m. Eastern Time (ET).

    QLT Inc. is a global biopharmaceutical company dedicated to the
discovery, development and commercialization of innovative therapies. Our
research and development efforts are focused on pharmaceutical products in the
fields of ophthalmology and dermatology. In addition, we utilize three unique
technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with
drugs, to create products such as Visudyne(R) and Eligard(R) and future
product opportunities. For more information, visit our web site at

    Conference call information

    QLT Inc. will hold an investor conference call to discuss year end
results for 2007 on Thursday, February 21 at 8:30 a.m. ET (5:30 a.m. PT). The
call will be broadcast live via the Internet at www.qltinc.com. To participate
on the call, please dial 1-800-319-4610 (North America) or 604-638-5340
(International) before 8:30 a.m. ET. A replay of the call will be available
via the Internet and also via telephone at 1-800-319-6413 (North America) or
604-638-9010 (International), access code 7142, followed by the number sign.

    A full explanation of how QLT determines and recognizes revenue resulting
from Visudyne sales is contained in the financial statements contained in the
periodic reports on Forms 10-Q and 10-K, under the heading "Significant
Accounting Policies - Revenue Recognition." Visudyne sales are product sales
by Novartis under its agreement with QLT.

    Atrigel is a registered trademark of QLT USA, Inc.
    Visudyne is a registered trademark of Novartis AG.
    Eligard is a registered trademark of Sanofi-Synthelabo Inc.

    QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol
    "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

    The Visudyne(R) sales figures in this press release are preliminary and
    unaudited and are not a complete disclosure of our annual financial

For further information:

For further information: QLT Inc.: Vancouver, Canada, Tamara Hicks, or
Therese Hayes, Telephone: (604) 707-7000, or 1-800-663-5486, Fax: (604)

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890